share_log
Moomoo 24/7 ·  03/11 07:21

Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review

Plus Therapeutics已经完成了Rhenium(186Re)Obisbemeda针对实体瘤轻脑膜转移的第5组Rhenium(186Re)1期剂量递增试验;该公司预计在标准安全审查后将于2024年第二季度进入第6队列

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发